United States Patent 9,545,414 (10,545,414) Scope and Claims Analysis: Tenofovir DF + Efavirenz + Emtricitabine Unitary Compartment Dosage Forms
Executive summary
US 9,545,414 claims a unitary oral anti-HIV dosage form that combines tenofovir DF with efavirenz and emtricitabine using a two-compartment architecture where the compartments are not in direct admixture. Claim scope is anchored by (i) compartmentalization (with or without a barrier layer), (ii) composition constraints (including specific surfactant options and weight-based ranges), and (iii) manufacturing/format parameters (layered and tablet weight limits, specific granulation processes). The estate’s practical leverage is in restricting not only “what actives are present,” but how they are physically combined to manage stability or bioavailability.
What does US 9,545,414 claim cover: unitary dosage forms with non-admixed compartments of tenofovir DF and efavirenz plus emtricitabine?
Core claim theme (Claim 1): a unitary dosage form containing:
- Tenofovir DF in a first compartment
- Efavirenz plus a surfactant in a second compartment
- Emtricitabine further included (not explicitly assigned to a specific compartment in Claim 1 text you provided)
- First and second compartments are not in direct admixture
Claim 1 is the infringement center of gravity. All dependent claims narrow from that baseline by specifying:
- barrier presence/absence
- bilayer architecture and orientation
- tablet weight
- manufacturing processes for each compartment
- specific surfactant identity
- composition percentages
- bioequivalence framing to Truvada + Sustiva exposure metrics
- containerization (desiccant)
Claim 1 elements mapped to infringement handles
| Claim 1 element |
What must be present to read on |
| Unitary dosage form |
Single administered dosage unit (tablet/caplet form implied by dependent claims) |
| Two compartments |
A structural division of actives |
| Tenofovir DF in first compartment |
Tenofovir DF located in compartment 1 |
| Efavirenz + surfactant in second compartment |
Efavirenz in compartment 2, surfactant included with it |
| Not in direct admixture |
No direct mixing or continuous homogeneous blend between compartments |
| Emtricitabine “further comprising” |
Present in dosage form; physical placement not required by the provided Claim 1 text |
Practical implication: designing around is more about avoiding compartmentalized non-admixed placement than about swapping surfactants (though Claim 8 and other dependent claims matter).
Do the dependent claims require a barrier layer or is direct adjacency allowed in US 9,545,414?
Claim set splits into two alternatives:
- Claim 2: “no barrier layer between the first component and the second component.”
- Claim 3: “a barrier layer between the first component and the second component.”
Legal/claim construction effect: both physical architectures are explicitly captured. This eliminates a common design-around tactic where a competitor tries to argue “we used no barrier so we are outside scope” or “we used a barrier so we are outside scope.” The text you provided makes both pathways part of the asserted claim family.
What “barrier layer” vs “no barrier layer” likely covers in practice
Even without file history, the claim language indicates two embodiments:
- Adjoining compartments (Claim 2): separation is achieved structurally without an intermediate film or membrane layer
- Separated compartments (Claim 3): explicit barrier layer forms a physical isolation boundary
Design-around pressure point: competitors must avoid the broader requirement that compartments are not in direct admixture in the first place. If they fully admix actives, they fall outside the Claim 1 architecture.
What tablet architectures are covered: bilayer tablets, horizontal layer orientation, and “layers” claim scope?
Layering and bilayer format
- Claim 4: compartments “are layers”
- Claim 6: bilayer tablet weighing < about 2.5 grams
- Claim 15: layers “oriented horizontally along an axis of the tablet”
Infringement risk increases as a competitor’s product resembles a compressed bilayer or laminated tablet with stable separation.
Weight and geometry constraints
- Claim 6: bilayer tablet < 2.5 g
- Claim 14: unitary dosage form weighs 1200 mg to 2300 mg (including optional film coating)
These two dependent claims are consistent and mutually supportive for a tablet embodiment. A competitor product falling outside these ranges can still infringe Claim 1 if it satisfies Claim 1 elements, but then it avoids certain narrower dependent claim fallbacks.
Which specific manufacturing methods are claimed: high shear wet granulation and dry granulation for the compartments?
- Claim 7: second compartment produced by high shear wet granulation
- Claim 9: first compartment produced by dry granulation
Scope note: these manufacturing limitations are in dependent form. A product that uses different process steps may avoid those dependent claims but can still fall under Claim 1 if the two-compartment non-admixture structure is used.
Design-around lever: process divergence may be a safer clearance path if architecture cannot be avoided, but it does not negate the structural limitations of Claim 1.
Which surfactants and excipients are explicitly claimed for the second compartment?
Surfactant specificity
- Claim 8: surfactant is sodium lauryl sulfate
This claim creates a strong “specific formulation” hook. Competitors using a different surfactant may not read on Claim 8, but they can still read on Claim 1 if a surfactant is present in the second compartment (Claim 1 requires “a surfactant,” not a specific one).
Additional excipients
Scope implication: these dependent claims target a commercially plausible composition. A competitor can reduce risk by avoiding those excipient selections and those weight proportions, but Claim 1 remains broader.
What composition-weight thresholds are claimed for efavirenz, emtricitabine, and tenofovir DF?
- Claim 10: total amount of efavirenz + emtricitabine + tenofovir DF is > about 60% by weight
- Claim 17: total amount of efavirenz + emtricitabine + tenofovir DF is about 70% by weight
These provide numerical guardrails. They matter for validity and infringement strategy if a competitor argues composition differences.
Does US 9,545,414 require pharmacokinetic equivalence to Truvada and Sustiva?
- Claim 13: oral administration provides substantially the same AUC and Cmax as FDA-approved products Truvada and Sustiva.
This is a dependent claim that introduces a pharmacokinetic performance requirement into the claim scope. In litigation, such language can create evidentiary burdens (PK studies) and may increase the leverage of claimants with in vivo data.
Design-around lever: if a competitor’s formulation changes release profile sufficiently, it may avoid Claim 13 while still potentially infringing other structural claims.
What containers are covered: desiccant packaging requirements?
- Claim 16: container comprising the unitary dosage form of Claim 1 and a desiccant.
If an accused product ships without desiccant packaging, that dependent claim may not be met. But again, Claim 1 remains the base structural claim.
What method-of-use claims exist and what dosing frequency is specified?
- Claim 18: administering the dosage form of Claim 1 for anti-HIV therapy
- Claim 19: dosage form administered only once daily
These method claims provide a pathway to infringement through prescribing and administration patterns, assuming the dosage form itself meets Claim 1.
Commercial impact: once-daily dosing is standard for many HIV regimens; the “only once daily” language narrows it.
How broad is the claim scope across “what” and “how”: actives vs architecture vs process?
Scope hierarchy
- Claim 1 (broadest structural anchor): unitary oral unit + two non-admixed compartments + tenofovir DF in compartment 1 + efavirenz + surfactant in compartment 2 + emtricitabine present
- Dependent claims add:
- barrier/no barrier (Claim 2/3)
- layered/bilayer/orientation (Claims 4/6/15)
- manufacturing processes (Claims 7/9)
- specific surfactant (Claim 8)
- specific excipients and wt% (Claims 11/12)
- PK equivalence (Claim 13)
- quantitative total-active wt% (Claims 10/17)
- weight ranges (Claims 6/14)
- desiccant packaging (Claim 16)
- once-daily dosing method limits (Claims 19)
Bottom line: the strongest infringement risk usually comes from matching the two-compartment, non-admixture architecture with the “tenofovir DF vs efavirenz+sufactant” compartment assignment.
What is the likely patent landscape relevance: how US 9,545,414 fits among Tenofovir DF + Emtricitabine + Efavirenz combination product strategies in the US?
US 9,545,414 is structurally aimed at an all-in-one fixed-dose combination that mimics the clinical efficacy of separated therapies (Truvada + Sustiva) through controlled physical arrangement. The claim family’s architecture-based restrictions are typical of formulation patents seeking to block direct substitution even when the same actives are used.
Litigation and licensing posture (what this claim set tends to be used for)
- Formulation blocking against generic “same actives, different tablet” attempts, when generics try to use physical admixture or simpler blend strategies.
- Design-around disputes focused on whether compartments are “not in direct admixture,” whether a barrier exists, and whether layering/bilayer orientation is present.
- Method-of-use hooks can add leverage if dosing regimen matches the once-daily limitation.
Because you supplied only claim text (not bibliographic data, assignee, filing/publication details, or prosecution history), the landscape can’t be mapped to specific co-pending siblings, continuation status, or litigation dockets with precision.
How strong is the patent estate for US 9,545,414: what claims are easiest to prove and what create proof burdens?
Easiest to prove (high evidentiary accessibility)
- Compartment structure: layered/bilayer architecture, barrier vs no barrier, horizontal orientation (Claims 2-4, 6, 15)
- Presence of specified excipients and surfactants (Claims 8, 11-12)
- Tablet weight ranges (Claims 6, 14)
- Desiccant packaging (Claim 16)
Higher proof burden
- Manufacturing process limitations (Claims 7, 9) require process evidence
- PK equivalence to Truvada/Sustiva (Claim 13) requires pharmacokinetic data
- Method claim “only once daily” requires regimen evidence (Claim 19)
Practical “claim coverage” conclusion
The strongest practical scope is Claim 1 plus architecture-adjacent dependent claims. The most litigable proof tends to favor structure and composition; performance and process claims increase the need for technical evidence.
Generic entry risk scenarios: where would a competitor most likely avoid infringement vs fail?
Scenario A: competitor uses a conventional homogeneous fixed-dose tablet
- If actives are blended into a direct admixture: likely avoids the “not in direct admixture” element of Claim 1.
- Risk depends on whether any compartmentalization exists in manufacturing scale-down.
Scenario B: competitor uses bilayer/laminated tablet with separated compartments
- If it places tenofovir DF in one side and efavirenz + surfactant in another side without admixture: high risk for Claim 1.
- Barrier/no barrier does not provide safe harbor due to Claim 2/3.
Scenario C: competitor swaps surfactant away from sodium lauryl sulfate
- Avoids Claim 8 but not Claim 1 (which requires “a surfactant,” not specifically SLS).
Scenario D: competitor keeps architecture but changes excipient package or wt% totals
- Avoids dependent claims 10, 11, 12, 17.
- Still risk for Claim 1 unless they change the compartment architecture element.
Key Takeaways
- US 9,545,414’s infringement focus is a unitary oral fixed-dose combination built around two compartments that are not in direct admixture, with a tenofovir DF-first compartment and an efavirenz + surfactant-second compartment, plus emtricitabine.
- The claim design blocks a common design-around on separation method by covering both “no barrier layer” (Claim 2) and “barrier layer” (Claim 3).
- Narrow dependent claims add constraints on bilayer/tablet weight, layer orientation, specific granulation methods, sodium lauryl sulfate, excipient set and wt%, PK equivalence, desiccant container, and once-daily dosing.
- For a generic or 505(b)(2) formulation entrant, the highest infringement risk comes from matching the compartment architecture; formulation tweaks and excipient substitutions mainly reduce exposure to dependent claims, not necessarily Claim 1.
FAQs
-
What design-around most directly avoids US 9,545,414?
Using a formulation where efavirenz and tenofovir DF (and the relevant components) are in direct admixture, rather than in non-admixed compartments.
-
If a competitor uses a barrier film between layers, does it escape the patent?
No. The patent expressly covers both embodiments with and without a barrier layer (Claims 2 and 3).
-
Does changing sodium lauryl sulfate eliminate infringement?
It can avoid the specific surfactant-dependent claim (Claim 8), but Claim 1 still requires a surfactant in the second compartment.
-
Can a product avoid the patent by being outside the tablet weight range?
It may avoid certain dependent claims (Claims 6 and 14), but not Claim 1 if the compartment architecture and composition elements still read.
-
How can litigation leverage PK language like Claim 13?
Claim 13 ties to AUC and Cmax relative to Truvada and Sustiva; asserting parties can seek evidence that the accused product delivers substantially similar exposure.
References
- User-provided claim text for US Patent 9,545,414 (claims 1-19).
